Determination of Regulatory Review Period for Purposes of Patent Extension; AURORA EV-ICD

Primary source

Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.

Published

March 10, 2026

Issuing agencies

Health and Human Services DepartmentFood and Drug Administration

Full Text

<html>
<head>
<title>Federal Register, Volume 91 Issue 46 (Tuesday, March 10, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 46 (Tuesday, March 10, 2026)]
[Notices]
[Page 11557]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: C1-2026-02383]



[[Page 11557]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket Nos. FDA-2024-E-3535 and FDA-2024-E-3536]


Determination of Regulatory Review Period for Purposes of Patent 
Extension; AURORA EV-ICD

Correction

    In Notice Document 2026-02383, appearing on pages 5497 through 
5498, in the issue of Friday, February 6, 2026, make the following 
correction:
    On page 5497, in the second column, in the ADDRESSES section, in 
the 8th line, ``February 6, 2026'' should read ``April 7, 2026''.

[FR Doc. C1-2026-02383 Filed 3-9-26; 8:45 am]
BILLING CODE 0099-10-D


</pre></body>
</html>

View on FederalRegister.gov →Plain-text source

Indexed from Federal Register on March 10, 2026.

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.